½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1629586

¹ÙÀÌ¿À½Ã¹Ð·¯ ¼öŹÁ¦Á¶ ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, À¯Çüº°, ¼­ºñ½º À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°

Biosimilar Contract Manufacturing Market, By Product Type, By Application, By Type, By Service Type , By End User, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼öŹÁ¦Á¶ ½ÃÀåÀº 2024³â¿¡ 107¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2024-2031³â CAGRÀº 15.9%¸¦ º¸À̸ç, 2031³â¿¡´Â 300¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2023³â 2024³â ½ÃÀå ±Ô¸ð 107¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031³â
¿¹Ãø ±â°£ÀÎ 2024-2031³â CAGR : 15.90% 2031³â °¡Ä¡ ¿¹Ãø 300¾ï 3,000¸¸ ´Þ·¯
µµÇ¥. ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ Áö¿ªº° Á¡À¯À²(%)(2024³â)
Biosimilar Contract Manufacturing Market-IMG1

¹ÙÀÌ¿À½Ã¹Ð·¯¶õ ÀÌ¹Ì ½ÂÀÎµÈ »ý¹°Á¦Á¦(ÂüÁ¶ Á¦Á¦ ¶Ç´Â ¿À¸®Áö³Î Á¦Á¦)¿Í Ä¡·á È¿°ú°¡ ¸Å¿ì À¯»çÇϵµ·Ï ¼³°èµÈ »ý¹°Á¦Á¦ÀÔ´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯´Â ¿©·¯ È÷Æ®ÀÛÀÇ Æ¯Çã°¡ ¸¸·áµÊ¿¡ µû¶ó ¹ÙÀÌ¿À½Ã¹Ð·¯¸¦ ÅëÇØ È¯ÀÚµéÀÌ º¸´Ù Àú·ÅÇÑ ÀÇ·á ¼­ºñ½º¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¼öŹÁ¦Á¶¾÷ü(CMO)´Â Á¦¾àȸ»ç°¡ ¹ÙÀÌ¿À½Ã¹Ð·¯ »ý»ê °øÁ¤À» °³¹ßÇÏ°í ±Ô¸ð¸¦ È®´ëÇÏ¿© ¾ö°ÝÇÑ Ç°Áú ±âÁØÀ» ÃæÁ·ÇÏ´Â ¹ÙÀÌ¿À½Ã¹Ð·¯¸¦ »ý»êÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Á¶¸¦ CMO¿¡ ¸Ã±â¸é Á¦¾à»ç´Â ¿¬±¸°³¹ß µî ÇÙ½É ¿ª·®¿¡ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

¼¼°è ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â °ÍÀº »ý¹°Á¦Á¦ÀÇ Æ¯Çã ¸¸·á·Î ÀÎÇÑ Àú·ÅÇÑ °¡°ÝÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ºñ¿ë È¿À²¼ºÀÌ ³ôÀº ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ±×·¯³ª ¹ÙÀÌ¿À½Ã¹Ð·¯ Á¦Á¶ ½Ã¼³ ¼³Ä¡¿¡ ³ôÀº ¼³ºñÅõÀÚ°¡ ÇÊ¿äÇÏ°í, ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ ±ÔÁ¦ ±âÁصµ ±î´Ù·Î¿ö ½ÃÀå ÁøÀÔ¿¡ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¶óƾ¾Æ¸Þ¸®Ä« µî ½ÅÈï ½ÃÀåÀº ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ°í, ȯÀÚµéÀÌ ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖÀ¸¸ç, Å« ¸ÅÃâ ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. °è¾à Á¦Á¶¾÷ü´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ¼¼Æ÷ÁÖ °³¹ßºÎÅÍ »ó¾÷Àû »ý»ê±îÁö ¿£µåÅõ¿£µå ¼­ºñ½º¸¦ Á¦°øÇÏ¿© ½ÃÀå °³Ã´À» Áö¿øÇÒ ¼ö ÀÖ´Â ±âȸ°¡ ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Ư¡

ÀÌ º¸°í¼­´Â ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼öŹÁ¦Á¶ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2023³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2024-2031³â)ÀÇ ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇص帳´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °í·Á»çÇ×µµ Á¦°øÇÕ´Ï´Ù.

¼¼°è ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

º» Á¶»çÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷¿¡´Â Biocon, Amgen, Pfizer, Boehringer Ingelheim, Lonza, Catalent, Wuxi Biologics, AbbVie, Merck KGaA, Rentschler Biopharma, Almac Group, Fujifilm Diosynth Biotechnologies, Evonik Industries, Avid Bioservices µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÀÌ ¸®Æ÷Æ®·ÎºÎÅÍÀÇ ÀλçÀÌÆ®¿¡ ÀÇÇØ ¸¶ÄÉÆà ´ã´çÀÚ ¹× ±â¾÷ÀÇ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆà Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±â¹ÝÇÑ ÀÇ»ç°áÁ¤À» ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼öŹÁ¦Á¶ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü¿©ÀÚ, À繫 ¾Ö³Î¸®½ºÆ® µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¿¡ ´ëÀÀÇÏ°í ÀÖ½À´Ï´Ù.

ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • °³¿ä

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ

Á¦4Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ °è¾à Á¦Á¶ ½ÃÀå, Á¦Ç° À¯Çüº°, 2019-2031³â,(10¾ï ´Þ·¯)

  • ÀçÁ¶ÇÕ ºñ´çÈ­ ´Ü¹éÁú
  • ÀçÁ¶ÇÕ ´çÈ­ ´Ü¹éÁú

Á¦5Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ °è¾à Á¦Á¶ ½ÃÀå, ¿ëµµº°, 2019-2031³â,(10¾ï ´Þ·¯)

  • Á¾¾çÇÐ
  • ´ç´¢º´
  • °¨¿°Áõ
  • ¸¸¼ºÁúȯ ¹× ÀÚ°¡¸é¿ªÁúȯ
  • Ç÷¾× Áúȯ
  • ¼ºÀåÈ£¸£¸ó ºÐºñ ºÎÀüÁõ

Á¦6Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ °è¾à Á¦Á¶ ½ÃÀå, À¯Çüº°, 2019-2031³â,(10¾ï ´Þ·¯)

  • Æ÷À¯·ù ¼¼Æ÷¿¡ ÀÇÇÑ Á¦Á¶
  • ¹Ì»ý¹°¿¡ ÀÇÇÑ Á¦Á¶

Á¦7Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ °è¾à Á¦Á¶ ½ÃÀå, ¼­ºñ½º À¯Çüº°, 2019-2031³â,(10¾ï ´Þ·¯)

  • ¾÷½ºÆ®¸² ÇÁ·Î¼¼½º
  • ´Ù¿î½ºÆ®¸² ÇÁ·Î¼¼½º
  • ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÇè
  • ¹ÙÀÌ¿À¾î¼¼ÀÌ(in vitro/in vivo)
  • ÇÁ·Î¼¼½º °³¹ß
  • Fill & Finish

Á¦8Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ °è¾à Á¦Á¶ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2019-2031³â,(10¾ï ´Þ·¯)

  • ¹ÙÀÌ¿ÀÀǾàÇ° ±â¾÷
  • Á¦Á¶ ¼öŹ ±â°ü(CMO)
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ °è¾à Á¦Á¶ ½ÃÀå, Áö¿ªº°, 2019-2031³â, °¡Ä¡(10¾ï ´Þ·¯)

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • Samsung Biologics
  • Biocon
  • Amgen
  • Pfizer
  • Boehringer Ingelheim
  • Lonza
  • Catalent
  • Wuxi Biologics
  • AbbVie
  • Merck KGaA
  • Rentschler Biopharma
  • Almac Group
  • Fujifilm Diosynth Biotechnologies
  • Evonik Industries
  • Avid Bioservices

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

  • ¿î¸íÀÇ ¼ö·¹¹ÙÄû
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
  • COM(Coherent Opportunity Map)

Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç ¼Ò°³
KSA 25.01.21

The Global Biosimilar Contract Manufacturing Market is estimated to be valued at USD 10.70 Bn in 2024 and is expected to reach USD 30.03 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 15.9% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 10.70 Bn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 15.90% 2031 Value Projection: US$ 30.03 Bn
Figure. Biosimilar Contract Manufacturing Market Share (%), By Region 2024
Biosimilar Contract Manufacturing Market - IMG1

Biosimilars are biological products designed to have highly similar therapeutic effect to an already approved biologic product, known as the reference product or originator product. With the patent expiry of several blockbuster biologics, biosimilars provide an opportunity for patient access to more affordable healthcare. Contract manufacturing organizations (CMOs) aid pharmaceutical companies in manufacturing biosimilars to exacting quality standards through process development and scaling up. Offloading biosimilar manufacturing to CMOs allows drug makers to focus on core competencies such as R&D.

Market Dynamics:

The global biosimilar contract manufacturing market growth is driven by the growing demand for affordable biosimilars due to patent expiration of biologics and increasing focus on biosimilars due to their cost-effectiveness. However, high capital investment requirements for setting up biosimilar manufacturing facilities and stringent regulatory standards for biosimilars pose challenges to market players. On the other hand, emerging markets, such as Asia Pacific and Latin America, present significant revenue potential with improving healthcare infrastructure and patient access to biosimilars in these regions. Contract manufacturers have opportunities to provide end-to-end services from cell line development to commercial manufacturing of biosimilars and help expand market reach.

Key Features of the Study:

This report provides in-depth analysis of the global biosimilar contract manufacturing market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global biosimilar contract manufacturing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biocon, Amgen, Pfizer, Boehringer Ingelheim, Lonza, Catalent, Wuxi Biologics, AbbVie, Merck KGaA, Rentschler Biopharma, Almac Group, Fujifilm Diosynth Biotechnologies, Evonik Industries, and Avid Bioservices

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global biosimilar contract manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biosimilar contract manufacturing market

Market Segmentation

  • Product Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Recombinant Non-glycosylated Proteins
    • Recombinant Glycosylated Proteins
  • Application Insights (Revenue, USD Bn, 2019 - 2031)
    • Oncology
    • Diabetes
    • Infectious Diseases
    • Chronic and Autoimmune Disorders
    • Blood Disorders
    • Growth Hormonal Deficiency
  • Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Mammalian Manufacturing
    • Microbial Manufacturing
  • Service Type Insights (Revenue, USD Bn, 2019 - 2031)
    • Upstream Processing
    • Downstream Processing
    • Biosimilarity testing
    • Bioassay (in vitro/in vivo)
    • Process Development
    • Fill & Finish
  • End User Insights (Revenue, USD Bn, 2019 - 2031)
    • Biopharmaceutical Companies
    • Contract Manufacturing Organizations (CMOs)
    • Others
  • Regional Insights (Revenue, USD Bn, 2019 - 2031)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Biocon
    • Amgen
    • Pfizer
    • Boehringer Ingelheim
    • Lonza
    • Catalent
    • Wuxi Biologics
    • AbbVie
    • Merck KGaA
    • Rentschler Biopharma
    • Almac Group
    • Fujifilm Diosynth Biotechnologies
    • Evonik Industries
    • Avid Bioservices

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Biosimilar Contract Manufacturing Market, By Product Type
    • Global Biosimilar Contract Manufacturing Market, By Application
    • Global Biosimilar Contract Manufacturing Market, By Type
    • Global Biosimilar Contract Manufacturing Market, By Service Type
    • Global Biosimilar Contract Manufacturing Market, By End User
    • Global Biosimilar Contract Manufacturing Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Driver
    • Restraint
    • Opportunity
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • Product Launches/Approvals
    • PEST Analysis
    • PORTER's Analysis
    • Merger and Acquisition Scenario
    • Industry Trends

4. Global Biosimilar Contract Manufacturing Market, By Product Type, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Recombinant Non-glycosylated Proteins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Recombinant Glycosylated Proteins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Biosimilar Contract Manufacturing Market, By Application, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Infectious Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Chronic and Autoimmune Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Blood Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Growth Hormonal Deficiency
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Biosimilar Contract Manufacturing Market, By Type, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Mammalian Manufacturing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Microbial Manufacturing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Biosimilar Contract Manufacturing Market, By Service Type, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Upstream Processing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Downstream Processing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Biosimilarity testing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Bioassay (in vitro/in vivo)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Process Development
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Fill & Finish
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Biosimilar Contract Manufacturing Market, By End User, 2019-2031, (USD Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Biopharmaceutical Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Contract Manufacturing Organizations (CMOs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Biosimilar Contract Manufacturing Market, By Region, 2019 - 2031, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Service Type , 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Service Type , 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Service Type , 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Service Type , 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Service Type , 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Product Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Service Type , 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

10. Competitive Landscape

  • Samsung Biologics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Biocon
  • Amgen
  • Pfizer
  • Boehringer Ingelheim
  • Lonza
  • Catalent
  • Wuxi Biologics
  • AbbVie
  • Merck KGaA
  • Rentschler Biopharma
  • Almac Group
  • Fujifilm Diosynth Biotechnologies
  • Evonik Industries
  • Avid Bioservices

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦